文献速递颈动脉与弓上血管

鱼精蛋白用于经股动脉颈动脉支架术不增加血栓栓塞风险

Protamine use in transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events.
PubMed 文献 · J Vasc Surg · 2020-06-12

鱼精蛋白组与未使用组在卒中或死亡方面无统计学显著差异,且在症状性颈动脉狭窄患者中与更低的卒中或死亡风险相关。

要点

  • 经股动脉CAS中使用鱼精蛋白不增加院内卒中或死亡风险。
  • 症状性颈动脉狭窄患者使用鱼精蛋白与更低的卒中或死亡风险相关。
  • 出血并发症需干预或输血方面两组无统计学显著差异。

核心结论

  • 经股动脉CAS后使用鱼精蛋白逆转肝素不增加血栓栓塞事件风险。
  • 在症状性颈动脉疾病患者中,鱼精蛋白使用与更低的卒中或死亡风险相关。

研究设计与样本

  • 共17,429例患者,其中2,697例(15%)接受鱼精蛋白;构建2,300对倾向性评分匹配队列比较使用与未使用鱼精蛋白的患者。

主要发现

  • 需输血的出血并发症两组无统计学显著差异(1.2% vs 1.2%;RR 0.92;95%CI 0.53-1.61;P=0.78)。

关键数值与推荐

  • 主要结局为院内卒中或死亡;次要结局包括出血并发症、卒中、死亡、短暂性脑缺血发作、心肌梗死和充血性心力衰竭加重。
  • 出血并发症分类为需干预的出血或需输血的出血。

临床怎么用

  • 经股动脉CAS中可考虑使用鱼精蛋白逆转肝素,不增加血栓栓塞风险。
  • 对症状性颈动脉狭窄患者,鱼精蛋白使用可能与更低的卒中或死亡风险相关。

局限性

  • 回顾性研究设计,可能存在未测量混杂因素。
  • 仅评估院内结局,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protamine use in carotid endarterectomy has been shown to be associated with fewer perioperative bleeding complications without higher rates of thromboembolic events. However, the effect of protamine use on complications after transfemoral carotid artery stenting (CAS) is unclear, and concerns remain about thromboembolic events. METHODS: A retrospective review was performed for patients undergoing transfemoral CAS in the Vascular Quality Initiative from March 2005 to December 2018. We assessed in-hospital outcomes using propensity score-matched cohorts of patients who did and did not receive protamine. The primary outcome was in-hospital stroke or death. Secondary outcomes included bleeding complications, stroke, death, transient ischemic attack, myocardial infarction, and congestive heart failure exacerbation. Bleeding complications were categorized as bleeding resulting in intervention or blood transfusions. RESULTS: Of the 17,429 patients undergoing transfemoral CAS, 2697 (15%) patients received protamine. We created 2300 propensity score-matched pairs of patients who did and did not receive protamine. There were no statistically significant differences in stroke or death between the two cohorts (protamine, 2.5%; no protamine, 2.9%; relative risk [RR], 0.85; 95% confidence interval [CI], 0.60-1.21; P = .37). Protamine use was not associated with statistically significant differences in perioperative bleeding complications resulting in interventional treatment (0.9% vs 0.5%; RR, 2.10; 95% CI, 0.99-4.46; P = .05) or blood transfusion (1.2% vs 1.2%; RR, 0.92; 95% CI, 0.53-1.61; P = .78). There were also no statistically significant differences for the individual outcomes of stroke (1.8% vs 2.3%; RR, 0.78; 95% CI, 0.52-1.16; P = .22), death (0.9% vs 0.8%; RR, 1.17; 95% CI, 0.62-2.19; P = .63), transient ischemic attack (1.4% vs 1.3%; RR, 1.10; 95% CI, 0.67-1.82; P = .70), myocardial infarction (0.5% vs 0.4%; RR, 1.20; 95% CI, 0.52-2.78; P = .67), or heart failure exacerbation (1.0% vs 0.9%; RR, 1.05; 95% CI, 0.58-1.90; P = .88). Protamine use in patients presenting with symptomatic carotid stenosis was associated with lower risk of stroke or death (3.0% vs 4.3%; RR, 0.69; 95% CI, 0.47-0.998; P = .048), whereas there were no statistically significant differences in stroke or death with protamine use in asymptomatic patients (1.6% vs 1.0%; RR, 1.63; 95% CI, 0.67-3.92; P = .28). CONCLUSIONS: Heparin reversal with protamine after transfemoral CAS is not associated with an increased risk of thromboembolic events, and its use in symptomatic carotid disease is associated with a lower risk of stroke or death.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Liang P, Motaganahalli R, Swerdlow NJ, et al. Protamine use in transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events. J Vasc Surg. 2020. PMID: 32535154. doi:10.1016/j.jvs.2020.04.526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。